The clinical relevance of changes in the Montgomery–Asberg Depression Rating Scale using the minimum clinically important difference approach

References

• Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a re-examination. Am J Psychiatry 2000;157:1925–32
   PubMed Web of Science ®Google Scholar
• Katon W, Schulberg H. Epidemiology of depression in primary care. Gen Hosp Psychiatry 1992;14:237–48
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617–27
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. J Am Med Assoc 1997;277:333–40
   PubMed Web of Science ®Google Scholar
• Lepine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997;12:19–29
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 2005;30:445–60
   PubMed Web of Science ®Google Scholar
• Zetin M, Hoepner CT, Bjornson L. Rational antidepressant selection: applying evidence-based medicine to complex real-world patients. Psychopharmacol Bull 2006;39:38–104
   Google Scholar
• Niklson IA, Reimitz PE, Sennef C. Factors that influence the outcome of placebo-controlled antidepressant clinical trials. Psychopharmacol Bull 1997;33:41–51
   PubMedGoogle Scholar
• Cohen LS. Statistical power analysis for the behavioral sciences. Hillsdale (NJ): Erlbaum; 1988
   Google Scholar
• Bowden Cl, Davis J, Morris D, et al. Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania. Depress Anxiety 1997;6:26–30
   PubMedGoogle Scholar
• Copay AG, Subach BR, Glassman SD, et al. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007;7:541–6
   PubMed Web of Science ®Google Scholar
• Taylor SJ, Taylor AE, Foy MA, et al. Responsiveness of common outcome measures for patients with low back pain. Spine 1999;24:1805–12
   PubMed Web of Science ®Google Scholar
• Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry 1992;149:1046–52
   PubMed Web of Science ®Google Scholar
• Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608–19
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 2000;57:375–80
   PubMed Web of Science ®Google Scholar
• Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006;31:1841–53
   PubMed Web of Science ®Google Scholar
• Burback D, Molnar FJ, St John P, et al. Key methodological features of randomized controlled trials of Alzheimer’s disease therapy. Minimal clinically important difference, sample size and trial duration. Dementia Geriatr Cogn Disord 1999;10: 534–40
   PubMed Web of Science ®Google Scholar
• Meyer RJ. U.S. regulatory perspective on the minimal clinically important difference in chronic obstructive pulmonary disease. Journal of Chronic Obstructive Pulmonary Disease 2005;2:47–9
   Google Scholar
• Brozek JL, Guyatt GH, Schunemann HJ. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health Qual Life Outcomes 2006; 4:69
   Google Scholar
• Wyrwich KW. Minimal important difference thresholds and the standard error of measurement: is there a connection? J Biopharm Stat 2004;14:97–110
   PubMedGoogle Scholar
• Niklson IA, Reimitz PE. Baseline characteristics of major depressive disorder patients in clinical trials in Europe and United States: is there a transatlantic difference? J Psychiatr Res 2001;35:71–81
   PubMed Web of Science ®Google Scholar
• Eikermann A, Diener HC. Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine. Cephalalgia 2003;23:344–7
   PubMed Web of Science ®Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331–6
   PubMed Web of Science ®Google Scholar
• Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17:95–102
   Google Scholar
• Lepola UM, Loft H, Reines EH, et al. Escitalopram (10–20mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18:211–7
   PubMed Web of Science ®Google Scholar
• Sapin C, Fantino B, Nowicki ML, Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2004;2:20
   PubMedGoogle Scholar
• Nunnaly J, Bernstein I. Psychometric theory, 3rd ed. New York: McGraw-Hill; 1994
   Google Scholar
• Wyrwich KW, Tierney WM, Wolinski FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999;52:861–73
   Google Scholar